William Blair Has Pessimistic Outlook of CGEM Q3 Earnings

Key Points

• William Blair has significantly lowered its Q3 2025 earnings per share estimate for Cullinan Therapeutics from ($0.72) to ($0.86), aligning with expectations of worsening performance for the company.
• The latest quarterly results showed Cullinan Therapeutics missed the consensus estimate by posting earnings of ($1.07) per share, compared to the expected ($0.83).
• Analysts remain divided on the stock, with a total of five rated it as "buy," but various price targets range significantly from $22.00 to $33.00, reflecting differing outlooks on company performance.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities research analysts at William Blair reduced their Q3 2025 EPS estimates for shares of Cullinan Therapeutics in a research note issued to investors on Thursday, August 7th. William Blair analyst M. Phipps now expects that the company will post earnings of ($0.86) per share for the quarter, down from their previous estimate of ($0.72). The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.04) per share. William Blair also issued estimates for Cullinan Therapeutics' Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.91) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($0.94) EPS, FY2026 earnings at ($3.85) EPS, FY2027 earnings at ($3.57) EPS and FY2028 earnings at ($4.21) EPS.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.24).

Several other research firms also recently issued reports on CGEM. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, April 16th. UBS Group lowered their target price on shares of Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Finally, Stifel Nicolaus started coverage on shares of Cullinan Therapeutics in a research note on Wednesday, June 11th. They issued a "buy" rating and a $22.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $30.00.

Cullinan Therapeutics Stock Performance

Shares of NASDAQ:CGEM traded down $0.06 on Monday, hitting $7.58. 196,160 shares of the company were exchanged, compared to its average volume of 421,047. The company's 50 day moving average price is $7.96 and its two-hundred day moving average price is $8.32. Cullinan Therapeutics has a one year low of $6.85 and a one year high of $19.89. The firm has a market capitalization of $447.72 million, a price-to-earnings ratio of -2.35 and a beta of -0.08.

Hedge Funds Weigh In On Cullinan Therapeutics

Several large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in Cullinan Therapeutics by 580.9% in the fourth quarter. JPMorgan Chase & Co. now owns 198,214 shares of the company's stock valued at $2,414,000 after purchasing an additional 169,104 shares in the last quarter. Wellington Management Group LLP increased its stake in Cullinan Therapeutics by 25.4% in the fourth quarter. Wellington Management Group LLP now owns 132,976 shares of the company's stock valued at $1,620,000 after purchasing an additional 26,951 shares in the last quarter. Geode Capital Management LLC increased its stake in Cullinan Therapeutics by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,214,641 shares of the company's stock valued at $14,798,000 after purchasing an additional 6,220 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in Cullinan Therapeutics in the fourth quarter valued at approximately $286,000. Finally, Wells Fargo & Company MN increased its stake in Cullinan Therapeutics by 47.9% in the fourth quarter. Wells Fargo & Company MN now owns 24,864 shares of the company's stock valued at $303,000 after purchasing an additional 8,056 shares in the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.